UCLA Study Investigates Creatine's Potential to Enhance Immune Response in Cancer
New research from UCLA indicates that creatine, a supplement often associated with muscle building, may enhance the immune system's capacity to fight cancer by improving the function of dendritic cells. This study, published in the journal iScience on July 8, highlights how creatine boosts energy levels in dendritic cells, enabling them to activate killer T cells more effectively against tumors. Lili Yang, a professor at UCLA and a member of the Broad Stem Cell Research Center, led the study, which builds on previous findings that demonstrated creatine's energizing effects on T cells.
Yang noted that creatine does not only support T cells in their fight against cancer; it also energizes the entire infrastructure that guides them. Current cancer immunotherapies activate T cells but are effective for only 20% to 40% of patients. Dendritic cells are vital for detecting tumors and orchestrating T cell responses, so enhancing their function could potentially extend the benefits of immunotherapy to a larger patient population.
The researchers observed that the gene responsible for the creatine transporter was more active in dendritic cells that infiltrated tumors compared to those in healthy tissue, suggesting a heightened demand for creatine in the tumor environment. In experiments with mouse models of melanoma, daily injections of creatine were found to slow tumor growth and increase both the number and activity of dendritic cells within the tumors. Metabolomic analyses revealed that creatine elevated intracellular ATP levels in dendritic cells, providing the necessary energy for inflammatory signaling pathways that activate immune responses.
ATP, or adenosine triphosphate, is the primary energy currency of cells, and its production is critical for cellular function. Creatine's established role in cellular energy metabolism is significant, as it helps regenerate ATP, which is essential for high-energy-demand cells, including muscle fibers and, as this study suggests, dendritic cells.
In laboratory settings, creatine also enhanced the activation of human monocyte-derived dendritic cells, which are commonly utilized in developing dendritic cell cancer vaccines. Furthermore, it improved these cells' ability to stimulate human T cells against cancer-associated targets. James Elsten-Brown, co-first author of the study, remarked that incorporating creatine during the production of dendritic cell vaccines could enhance their effectiveness. He emphasized that creatine could serve a dual purpose: as a supplement to boost the immune response in patients undergoing immunotherapy and as a tool to improve the quality of dendritic cell-based vaccines before administration.
The idea of using nutritional supplements to bolster immune function during cancer treatment is gaining traction. Another natural compound, trans-vaccenic acid found in meat and dairy, has been shown to improve cancer outcomes by infiltrating tumors and killing cancer cells, according to research from the University of Chicago. These findings underscore a broader role for diet and supplementation in cancer care.
However, the researchers caution that this study is in its early stages. All experiments were conducted in mice and human cells in laboratory settings, not in actual cancer patients, meaning the results do not confirm that creatine supplements will enhance cancer treatment in humans. While creatine monohydrate is generally considered safe at recommended doses, individuals undergoing cancer treatment should consult a physician before using any supplements. The next phase will involve prospective clinical trials to determine if creatine can improve outcomes for patients receiving immunotherapy. This approach has not yet received approval from the Food and Drug Administration, and a patent application has been filed by UCLA. Creatine is already widely used as a supplement for athletic performance, and its safety profile is well-documented, but specific applications for cancer therapy require rigorous testing. Patients are advised against self-medicating with creatine in the hopes of achieving anti-cancer effects based on these preliminary findings.




